• Arqule Inc., of Medford, Mass., said it is collaborating with Monsanto Co., of St. Louis, to develop agrochemicals. Arqule will receive $12 million to provide Monsanto with mapping array compound sets and will synthesize directed array compound sets for use in the development of crop protection products.

ImmuLogic Pharmaceutical Corp., of Waltham, Mass., has filed an investigational new drug application for a multiple sclerosis drug. The company said it plans to begin Phase I trials in the second quarter of 1997. ImmuLogic’s drug is aimed at turning off the T cells which trigger the inflammatory response that destroys the myelin sheath surrounding nerves.

Incyte Pharmaceuticals Inc., of Palo Alto, Calif., has signed another customer for its LifeSeq DNA sequence and gene expression data base. Genentech Inc., of South San Francisco, joins a group of 11 companies that have acquired rights to use the data base. Terms of the agreement were not disclosed.

Interferon Sciences Inc., of New Brunswick, N.J., completed a private placement raising $9.1 million. The 5.6 million shares were placed through Sunrise Securities Corp. The new funds will be used to further advance work on Interferon’s Alferon N, a treatment for HIV and hepatitis C.

Isis Pharmaceuticals Inc., of Carlsbad, Calif., has received a second milestone payment from Boehringer Ingelheim GmbH, of Ingelheim, Germany, as part of a collaboration to develop drugs to treat inflammatory diseases. Isis received $7.9 million as part of a line of credit of up to $40 million. In December, the company received $10 million following the completion of a Phase IIa trial of ISIS 2302 for Crohn’s disease.

Monsanto Co.. of St. Louis, said it has agreed to acquire Holden’s Foundation Seeds Inc., Corn States Hybrid Service Inc. and Corn States International S.a.r.l. for up to $1.02 billion. Monsanto, which said in December that it plans to spin off its chemical business, has invested nearly $2 billion in the last two years in agribiotech, including Calgene Inc., of Davis, Calif., and DeKalb Genetics Corp., of DeKalb, Ill.

SIBIA Neurosciences Inc. and Aurora Biosciences Corp., both of La Jolla, Calif., said they have entered into a cross-licensing agreement for certain assay technologies. Terms indicate that SIBIA will license to Aurora non-exclusive rights to practice its transcription-based assay technology. In return, SIBIA will receive non-exclusive rights to several assay technologies, including novel reporter molecules, from Aurora. Financial details were not disclosed.

Sugen Inc., of Redwood City, Calif., has filed an investigational new drug application for SU5271, a treatment for psoriasis. The compound is a synthetic small molecule signal transduction inhibitor that blocks keratinocyte growth. A Phase I trial is planned for this year at Mount Sinai Hospital in New York.